A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer
Voluntarily participate in the clinical trial; fully understand and be informed about this study and sign the informed consent form;
At the time of screening, the age should be between 18 and 75 years old (inclusive), regardless of gender;
Patients with histologically confirmed stage IIIA NSCLC (T4N0M0, T3-4N1M0, T1a-2bN2M0) who underwent R0 resection and received postoperative adjuvant chemotherapy (Exclusion of EGFR sensitizing mutations and ALK fusion); and who received the first dose of PANK-003 cell injection combined with postoperative adjuvant chemotherapy within 8 weeks after radical surgery.;
At the time of enrollment, the expected survival time is more than 6 Months;
NSCLC patients who have received neoadjuvant therapy;
Pregnant or lactating women;
Cured non-melanoma skin cancer
Carcinoma in situ of the cervix